GN-HEARING
1.2.2021 09:02:06 CET | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils ReSound Key, a full essential hearing aid line-up that provides greater access to proven and award-winning hearing technology worldwide. Based on an advanced chip platform and GN’s Organic Hearing philosophy, ReSound Key promises clear, natural sound quality. It is also packed with the latest technology, such as rechargeable options and state-of-the-art streaming, so that more people can now stay connected to live life to the fullest.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005069/en/
Today, only one in five of those who could benefit from hearing aids are using themi , leaving a large proportion to miss out on life’s sounds, communicating with family, and socializing with friends. The long-awaited ReSound Key is set to make a huge difference to people with all types of hearing loss. People can boost their confidence and connect with others and the world during times of social isolation; all with clear sound and leading rechargeability that offers up to 30 hours of power from one charge. They can enjoy direct streaming using iOS and Android™ devices and state-of-the-art Bluetooth® Low Energy.
Not treating hearing loss comes at a personal cost, with implications for physical, social, emotional, and mental health.ii,iii,iv However, professional guidance is at hand, even remotely, thanks to the innovative telehealth solution, ReSound Assist Live. With this agile at-home service, hearing care professionals can program and adjust ReSound Key hearing aids via video consultations to help people grow with their hearing and nurture their relationships.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we believe that everyone deserves great hearing. Treating hearing loss can radically transform lives, helping people to thrive and grow. The launch of ReSound Key gives more people access to the best care and professional guidance, which helps them feel more confident and stay in touch with others to participate fully in life.”
ReSound Key joins the groundbreaking ReSound ONETM with M&RIE* and ReSound LiNX Quattro™ in the strongest and broadest ReSound portfolio yet, which offers premium hearing solutions at all price levels. Now more people can benefit from the company’s long-standing Organic Hearing philosophy to connect with the world around them in the most intuitive and natural way, which is inspired by how the ear works and the natural ways we listen.
Working with intuitive apps, ReSound Key further enhances the individualized hearing experience and can connect to a range of wireless accessories for additional help in challenging listening situations. New integrated, streamlined fitting and software updates ensure a seamless first fit and customer satisfaction. These updates make it easier than ever to offer the ReSound portfolio for users to enjoy.
ReSound Key is available in 10 models, including the popular rechargeable Receiver-in-Ear (RIE) design, custom hearing aids, and Behind-the-Ear (BTE) options – even including high power and super power models for profound hearing loss. ReSound Key will roll out in markets around the world from February 1, 2021. The same technology and models are also available in the new Beltone Rely hearing aid portfolio.
For further information, visit the ReSound Newsroom and learn about the Organic Hearing philosophy. A ReSound Virtual Conference is hosted for hearing care professionals in the United States on February 2, 2021.
– ENDS –
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn and Facebook .
*ReSound ONE introduced the world’s first full-featured hearing aid with M&RIE. Microphone and Receiver In Ear, for a truly individualized, more complete sound experience. ‘Full-featured’ means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.
© 2021 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC. Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc
i World Health Organization (WHO) 2020: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
ii Hearing loss and incident dementia. Lin et al 2011
iii The impact of communication impairments on the social relationships of older adults: Pathways to psychological well-being. Palmer et al 2019
iv Hearing loss and associated medical conditions among individuals 65 years and older. McKee et al 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom